دورية أكاديمية
أعرض في EDS

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

التفاصيل البيبلوغرافية
العنوان: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
المؤلفون: Adam Lauko, Rupesh Kotecha, Addison Barnett, Hong Li, Vineeth Tatineni, Assad Ali, Pradnya Patil, Alireza M. Mohammadi, Samuel T. Chao, Erin S. Murphy, Lilyana Angelov, John H. Suh, Gene H. Barnett, Nathan A. Pennell, Manmeet S. Ahluwalia
المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
بيانات النشر: Nature Portfolio, 2021.
سنة النشر: 2021
المجموعة: LCC:Medicine
LCC:Science
مصطلحات موضوعية: Medicine, Science
الوصف: Abstract Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs within 90 days of NSCLCBM diagnosis (ICI-90) and compared them to patients who never received ICIs (no-ICI). We reviewed 800 patients with LCBM who were diagnosed between 2010 and 2019 at a major tertiary care institution, 97% of whom received stereotactic radiosurgery (SRS) for local treatment of BM. OS from BM was compared between the ICI-90 and no-ICI groups using the Log-Rank test and Cox proportional-hazards model. Additionally, the impact of KRAS mutational status on the efficacy of ICI was investigated. After accounting for known prognostic factors, ICI-90 in addition to SRS led to significantly improved OS compared to no-ICI (12.5 months vs 9.1, p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-021-97566-z
URL الوصول: https://doaj.org/article/e1027f0afb7f466d803752a48a7d5614
رقم الأكسشن: edsdoj.1027f0afb7f466d803752a48a7d5614
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20452322
DOI:10.1038/s41598-021-97566-z